TRIgnite-1 study shows an overall response rate (ORR) of 74% across nine dose levels, in heavily pretreated patients with a median of six prior lines of therapy ORR is remarkably high in patients with ...
- ISB 2001 is a first-in-class T cell-engaging (TCE) trispecific antibody based on Ichnos' proprietary BEAT ® platform that targets BCMA and CD38 on multiple myeloma (MM) cells. - ISB 2001 exhibited ...
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM Company will also present safety and tolerability data from Phase 1/2 study of ...
No dose-limiting toxicities were observed up to weekly subcutaneous doses of 1.2 mg/kg, with mostly mild Cytokine Release Syndrome, no cases of neurotoxicity, and no discontinuations due to adverse ...
Ichnos Sciences Inc. has presented data on the first-in-class trispecific BCMA and CD38 T-cell engager ISB-2001, which is based on the company’s TREAT (Trispecific Engagement by Antibodies based on ...
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics TM in oncology, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results